采用治疗-延长方案进行阿柏西普玻璃体内注射治疗新生血管性年龄相关性黄斑变性专家共识(2021版)  

Chinese experts consensus of treat-and-extend regimen for management of neovascular age-related macular degeneration by intravitreal injection of aflibercept (2021)

作　　者：阿柏西普玻璃体内注射治疗新生血管性年龄相关性黄斑变性的治疗-延长方案中国共识专家组 孙晓东[2] Treat-and-Extend Regimen for Management of Neovascular Age-related Macular Degeneration Chinese Experts Consensus Group;Sun Xiaodong

机构地区：[1]不详 [2]上海交通大学附属第一人民医院,国家眼部疾病临床医学研究中心,上海市眼底病重点实验室

出　　处：《中华实验眼科杂志》2021年第7期577-584,共8页Chinese Journal Of Experimental Ophthalmology

基　　金：上海申康医院发展中心项目(SHDC2020CR2040B、SHDC2020CR5014)。

摘　　要：新生血管性年龄相关性黄斑变性(nAMD)是临床上影响视力和致盲的重要原因之一。采用阿柏西普治疗—延长(T&E)方案治疗nAMD的疗效确切,可减少患者玻璃体内注射和随访次数,减轻医生随访和患者的经济负担。目前我国眼科临床医生对阿柏西普T&E治疗方案的优势、规范的治疗路径及在操作中的注意事项尚缺乏系统的了解,大大限制了该治疗方案在nAMD治疗中的推广范围、合理使用和患者获益。2020年初我国相关研究领域专家组成员在总结我国各级医疗机构采用阿柏西普T&E方案治疗nAMD存在的临床问题基础上,基于nAMD、发病机制以及药物作用机制,认真总结既往相关研究成果、充分复习国内外相关指南/共识,结合我国相关领域临床实践和国情讨论并制定本共识,形成使用阿柏西普T&E方案治疗nAMD推荐意见,以指导我国临床医师更好地理解并规范地采用T&E方案治疗nAMD。Neovascular age-related macular degeneration(nAMD)is one of the leading causes of visual impairment and blindness.Using treat-and-extend(T&E)regimen,aflibercept has been proven effective in nAMD treatment.Decreased intravenous injections and follow-up visits greatly reduce financial and follow-up burdens on nAMD patients as well as doctors.However,ophthalmologists in China still lack systematic understanding of the advantages,standardized treating pathway,clinical practice and patients'gains of aflibercept T&E regimen,which greatly limits the extensive promotion and rational use in nAMD treatment.At the beginning of 2020,experts in relevant research fields summarized clinical problems existing in nAMD treatment with aflibercept T&E regimen in China.Based on an extensive survey of the latest progress of nAMD treatment,pathogenesis,drug mechanism,previous relevant research results and guidelines/consensus at home and abroad,and in combination with clinical practice and national conditions in relevant fields in China,a consensus was discussed and formulated.This publication would provide a recommendation for nAMD treatment with aflibercept T&E regimen,which would be helpful for clinicians in China to better understand and standardize the application of aflibercept T&E regimen in nAMD treatment.

关 键 词：年龄相关性黄斑变性 血管内皮生长因子 脉络膜新生血管 治疗—延长方案 专家共识 阿柏西普 

分 类 号：R774.5[医药卫生—眼科]